Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cellsAdam J. Lamble, Nirali N. Shah, Regina M. Myers et al.|Blood Advances|2022Cited by 149
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapyEmily M. Hsieh, Regina M. Myers, Bonnie Yates et al.|Blood Advances|2022Cited by 34
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemiaSara Silbert, Marlie R. M. Provost, Stephan A. Grupp et al.|Blood|2025Cited by 33
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Rawan Faramand, Liora M. Schultz et al.|Blood Advances|2025Cited by 15
HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell AplasiaMichael W. Boyer, Jennifer Willert, Sonali Chaudhury et al.|Blood|2020Cited by 8